PS
XENE icon

Principal Securities’s Xenon Pharmaceuticals XENE Stock Holding History

Principal Securities’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-68
Closed -$2.73K – 3522
2025
Q3 		$2.73K Hold
68
– – ﹤0.01% 3159
2025
Q2 		$2.13K Buy
68
+10
+17% +$326 ﹤0.01% 3129
2025
Q1 		$2.27K Hold
58
– – ﹤0.01% 3014
2024
Q4 		$2.27K Buy
58
+13
+29% +$537 ﹤0.01% 3008
2024
Q3 		$1.77K Buy
45
+24
+114% +$968 ﹤0.01% 2987
2024
Q2 		$819 Buy
21
+5
+31% +$200 ﹤0.01% 3107
2024
Q1 		$689 Hold
16
– – ﹤0.01% 3099
2023
Q4 		$737 Buy
+16
New +$565 ﹤0.01% 3015

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Principal Securities's XENE Position: Q4 2025 in Review

Principal Securities sold out of Xenon Pharmaceuticals (XENE) in Q4 2025, closing a stake of 68 shares — an estimated $2.73K sold.

Principal Securities first reported a position in XENE in Q4 2023 and held it in 8 quarters. The position peaked at $2.73K in Q3 2025. 245 funds tracked by Wall St. Rank hold XENE as of Q4 2025.

  • Principal Securities reported no remaining Xenon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 68 Xenon Pharmaceuticals shares in Q4 2025, an estimated $2.73K.
  • Principal Securities first reported a position in Xenon Pharmaceuticals in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Xenon Pharmaceuticals position peaked at $2.73K in Q3 2025.
  • 245 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.